权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Systems and carcinogenic impact assessment of topical microbicides on human mucosa

局部杀菌剂对人体粘膜的系统和致癌影响评估

基本信息

批准号：
8922415
负责人：
Florian Hladik
金额：
$ 69.05万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-05-01 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8922415
关键词：
AIDS prevention Address Adverse effects Anti-Inflammatory Agents Anti-Retroviral Agents Anti-inflammatory Apoptosis Biological Assay Biopsy Cell Density Cell Differentiation process Cell Survival Cells Cervical Cervix Uteri Clinical Cross-Over Trials DNA Data Diphosphates Dose Drug Formulations Effectiveness Epithelial Cells Fluorescence Force of Gravity Frequencies Gel Gene Expression Gene Expression Profile Genital system Gilead brand of tenofovir disoproxil fumarate HIV HIV Infections Homeostasis Human Human Papillomavirus Human papilloma virus infection Human papillomavirus 16 Immune Immunodeficient Mouse Impairment Incidence Individual Inflammation Inflammation Mediators Inflammatory Interleukin-10 Intestinal Neoplasms Irritants Lead Leukocytes Licensure Local Microbicides Longitudinal Studies Malignant Neoplasms Malignant neoplasm of cervix uteri Mitochondria Modeling Mucous Membrane Mus Mutation Neoplastic Processes Nonoxynol 9 Oral Patients Pharmaceutical Preparations Phase Phase III Clinical Trials Placebos Prevention Prevention strategy Proliferating Prophylactic treatment Proteins Proteome Publishing Rectum Regulatory Pathway Relative (related person)Resistance Reverse Transcriptase Inhibitors Risk Rodent Route Safety Schedule Specimen Stimulus Suggestion System Systems Biology T-Lymphocyte TMC120-R147681 Tenofovir Testing Thymidine Time Tissues Topical application Toxic effect Transgenic Mice Vagina Vagina Carcinoma Vaginal Ring Woman Xenograft procedure Zidovudine arm carcinogenesis carcinogenicity cervicovaginal chemokine design digital ds-DNA efficacy trial follow-up in vitro Assay in vivo innovation microbicide mouse model neoplastic cell novel novel strategies nucleoside analog phase 1 study prevent protective efficacy public health relevance rectal repaired screening sexual HIV transmission tool tumor

项目摘要

DESCRIPTION (provided by applicant): Several antiretroviral drugs are being tested as topical microbicides for the prevention of sexual HIV transmission. Because effective HIV prophylaxis would entail frequent use of topical antiretroviral drugs by healthy individuals, such use would need to be safe. However, in a recent comprehensive assessment of 1% tenofovir gel in vivo, conducted in the MTN-007 trial, we uncovered that it had profound effects on gene expression in the rectal mucosa, suggesting important changes in gut immune and self-repair homeostasis. When we followed up on these results using human primary vaginal epithelial cells, we found very similar changes. These changes, in particular pronounced impairment of mitochondrial function and the prospect of carcinogenicity, have the potential to contraindicate the use of tenofovir, and potentially of other drugs of the same DNA chain terminator class, as a topical microbicide. It is therefore imperative to extensively and immediately expand on these findings in order to corroborate tenofovir's side effects on the mucosa, to determine whether pericoital use is safer than daily use, and to compare its effects on the rectal and vaginal mucosa in vivo. In Aim 1 of this proposal we will address these issues using systems biology approaches in two trials testing 1% tenofovir gel, MTN-014 and MTN-017, using rectal and vaginal tissue specimens. Besides indirect suggestions in our data that tenofovir could increase neoplastic processes in the mucosa, a large body of data has demonstrated that DNA chain terminator drugs, like tenofovir and azidothymidine, are carcinogenic and mutagenic in a dose-dependent manner. Because of the potential gravity of this effect and the high concentrations of active drug achieved in mucosal tissues after topical application (>2 logs higher than achieved by oral dosing), we propose in Aim 2 to directly investigate the mucosal carcinogenicity of topical tenofovir and to determine whether non-DNA chain terminators like dapivirine might be safer alternatives. We propose innovative approaches designed to overcome the limitations of traditional rodent carcinogenicity models, incorporate human primary mucosal epithelial cells, and include an assessment of human papilloma virus (HPV) as a co-factor in tenofovir-induced carcinogenesis. These studies will help determine the relative suitability of drugs like tenofovir as topical prevention agents in comparison to non-DNA chain terminators like dapivirine, and provide novel tools for the assessment of the mucosal safety profile of candidate microbicide drugs, including the likelihood of carcinogenicity. Should our study confirm that DNA chain terminator drugs are too risky for mucosal application, it is hoped that we will find drugs like dapivirine to be effective and safer alternatives.